

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number  
WO 01/64188 A1

(51) International Patent Classification<sup>7</sup>: A61K 9/16, 9/72

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(21) International Application Number: PCT/GB01/00834

(22) International Filing Date: 27 February 2001 (27.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0004827.2 29 February 2000 (29.02.2000) GB

(71) Applicant (for all designated States except US):  
QUADRANT HOLDINGS CAMBRIDGE LIMITED [GB/GB]; 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MARTYN, Glen, Patrick [GB/GB]; Quadrant Holdings Cambridge Limited, 1 Mere Way, Ruddington, Nottingham NG11 6JS (GB).

(74) Agent: GILL JENNINGS & EVERY; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 01/64188 A1

(54) Title: THERAPEUTIC COMPOSITIONS FOR PULMONARY DELIVERY

(57) Abstract: Microparticles that are obtainable by spray-freeze-drying a solution comprising a water-soluble, matrix-forming polymer and a therapeutic agent, may be useful for pulmonary delivery of the therapeutic agent.

## THERAPEUTIC COMPOSITIONS FOR PULMONARY DELIVERY

### Field of the Invention

The present invention relates to the manufacture of particles that may be used to deliver a therapeutic agent via the lung, and compositions thereof.

### 5 Background to the Invention

The delivery of therapeutic agents to a patient via the lung is now well established. Compositions for pulmonary delivery are usually aerosolised in an inhaler device, activated by inhalation from the patient. In order to deposit the active agent effectively within the lung, the inhalable compositions should 10 exhibit specific properties. For example, it is usually necessary to have inhalable particles of a small aerodynamic size and shape, and particle diameter of typically less than 20  $\mu\text{m}$ , and preferably less than 10  $\mu\text{m}$ . This is to ensure that the particles are able to penetrate deep within the lung. The compositions are usually in the form of powders which exhibit minimal 15 electrostatic activity, low hygroscopicity, and have good flow properties. It is also preferable that the therapeutic is in a sustained release formulation to maintain a constant release of the therapeutic over time, thus sustaining the therapeutic effect. For this reason, the therapeutic is often contained within a carrier material which exhibits these release properties.

20 Many different carriers have been proposed for use in pulmonary delivery. Carbohydrates and polysaccharides have long been considered good carrier materials as they can be formulated easily into stable compositions, and have good release properties. WO-A-98/43664 discloses the use of hyaluronic acid as a carrier material. Hyaluronic acid is stated to have good sustained-release properties. Although the main focus of the description is with respect 25 to injection formulations, there is mention of an aerosol formulation for delivery via the nose or bronchi mucus membrane. The manufacture of the compositions is shown to be by spray-drying.

30 Although the compositions may have suitable properties for pulmonary delivery, there is still a need for improved formulations to promote delivery of therapeutic agents delivered via the lung.

### Summary of the Invention

The present invention is based on the surprising finding that the process of spray-freeze-drying can be used to produce microparticles which exhibit beneficial properties for pulmonary delivery.

5 According to one aspect of the invention, microparticles are obtainable by spray-freeze-drying a solution or dispersion comprising a water-soluble, matrix-forming polymer and a therapeutic agent. Hyaluronic acid, or an inorganic salt thereof, is a particularly preferred polymer.

10 According to a second aspect of the invention, a composition for pulmonary delivery comprises microparticles as defined above, and a carrier material.

According to a third aspect, a device for delivery of a therapeutic agent via pulmonary inhalation comprises a microparticle as defined above.

15 According to a fourth aspect of the invention, a process for the preparation of microparticles for pulmonary delivery comprises spray-freeze-drying a solution or dispersion comprising a therapeutic agent and a water-soluble, matrix-forming polymer.

20 Spray-freeze-drying the matrix-forming polymer and therapeutic agent results in microparticles that are lighter than conventional spray-dried particles, with good porous characteristics and which are therefore better able to achieve deep lung deposition. High molecular weight polymers suitable for use in the invention also exhibit good mucoadhesive properties, and are therefore particularly suitable for pulmonary delivery. In addition, the polymers used to produce the microparticles have good controlled release properties, and are therefore more beneficial than conventional low molecular weight sugars for delivery via the pulmonary route. The spray-freeze-drying process results in improved recovery of the product compared to that recovered from conventional spray-drying methods.

### Description of the Invention

30 The present invention makes use of spray-freeze-drying technology to manufacture novel microparticles particularly suited to pulmonary delivery. The process of spray-freeze-drying involves the atomisation of a solution or

dispersion of the matrix-forming polymer and therapeutic agent, and then directing the resulting droplets into a liquified gas, typically liquid nitrogen. The droplets freeze on contact with the liquified gas and may then be dried using a freeze-drying step to remove residual moisture. The resulting microparticles  
5 comprise a therapeutic agent dispersed within the polymer matrix.

The apparatus and process conditions used to produce the initial droplets will be apparent to the skilled person. Feed concentrations, pump rates, atomisation pressures and nozzle types can all be selected based on conventional process conditions, and then optimised according to feedstock  
10 concentration and viscosity.

The size of the microparticles will be determined in part by the atomisation used in the spray-freeze-drying process. The atomisation/spraying stage may make use of a conventional atomisation process, e.g. pressure or two fluid nozzles, or may utilise an ultrasonic atomisation process (Maa *et al.*,  
15 Pharmaceutical Research, 1999; 16(2)). The microparticles will usually have a mean aerodynamic particle diameter size ranging from 0.1 to 40  $\mu\text{m}$ , preferably from 0.1 to 10  $\mu\text{m}$ , and most preferably from 0.1 to 5  $\mu\text{m}$ . This may be measured using a aerosizer (TSI Instruments) as will be appreciated by the skilled person.

20 The drying process may be carried out using conventional freeze-drying apparatus. Drying will usually be carried out to achieve a residual moisture content of the microparticles of less than 10% by weight, preferably less than 5% by weight and most preferably less than 3% by weight.

The matrix-forming polymer should be water-soluble, i.e. hydrophilic.  
25 High molecular weight polysaccharides are a preferred embodiment, as are gums and cellulose ethers. Hyaluronic acid is a particularly preferred polymer as it exhibits good mucoadhesive properties, is biocompatible and biodegradable, and is also able to avoid phagocytic uptake. Other suitable polymer materials include hydrogels, alginic acid, pectins, agarose, and  
30 polyvinylpyrrolidone.

As used herein, the reference to "matrix-forming polymer" is intended to mean that the polymer forms a stable, rigid, structure capable of retaining

molecules that may be dispersed therein. Polymers are typically made up of multiple repeating monomer units, typically greater than three monomer units. In the context of the present invention, high molecular weight polymers are greater than 250 kDa, preferably greater than 500 kDa, more preferably greater 5 than 1000 kDa and most preferably greater than 1500 kDa. High molecular weight, hydrophilic polymers are particularly suitable for pulmonary delivery as they offer beneficial controlled release properties, which ensures that a therapeutic agent, dispersed within the polymer, can be administered in a controlled manner over time. This is different from the use of conventional low 10 molecular weight sugars, e.g. monosaccharides and disaccharides, which may be rapidly soluble on administration.

The polymer should be physiologically acceptable. It is preferred if the polymer is capable of stabilising the therapeutic agent during the preparation of the microparticles and storage. This is particularly important when the therapeutic agent is a protein or peptide, which may be relatively labile. 15

The amount of polymer in the initial feedstock can be determined by the skilled person, depending on the properties required. Dilute concentrations are preferred, preferably 0.01% w/v to 20% w/v, more preferably 0.01% w/v to 1% w/v, most preferably 0.1% w/v to 0.5% w/v.

20 Any suitable therapeutic agent may be used in the present invention, as will be appreciated by the skilled person. Therapeutic agents which may be used include, for example, proteins, peptides, nucleic acids and small organic molecules. Anti-inflammatory compounds are preferred, as is insulin in its hexameric or monomeric form. The reference to therapeutic agents is intended 25 to also include prophylactic agents, including vaccines in the form of proteins or polypeptides, or attenuated microorganisms. Pharmaceutical agents that are particularly suitable for administration via the pulmonary route are preferred. In particular, antiallergics, bronchodilators, analgesics, antibiotics, antihistamines, antiinflammatories, steroids, cytokines, cardiovascular agents 30 and immunoactive agents.

It will be appreciated by the skilled person that the therapeutic agents are to be formulated in physiologically effective amounts. That is, when

delivered in a unit dosage form, there should be a sufficient amount of the therapeutic to achieve the desired response. As the microparticles of the invention are intended primarily for delivery as dry powders in an inhalation device, it will be appreciated that a unit dose comprises a predefined amount of microparticles delivered to the patient in one inspiratory effort. In a preferred embodiment, the microparticles are prepared as single unit dosage forms for inclusion in dry powder inhalers. In this embodiment, a single unit dose will be approximately 1 to 15 mg, preferably between 5 to 10 mg.

The amount of therapeutic agent present in each microparticle will be determined on the basis of the level of biological activity exhibited by the therapeutic agent. If the therapeutic agent has high activity, then there may be as little as 0.001% w/w of the agent with respect to the polymer material. Usually the microparticles will comprise greater than 5%, 20%, 30% or even 40% w/w of the therapeutic agent. The amounts can be controlled simply by regulating the concentration of the agent in solution with the polymer prior to the spraying step.

The composition to be spray-freeze-dried may also comprise other components, e.g. carbohydrates or other glass-forming substances as stabilisers or excipients. Additional components may be desirable to modify the characteristics of the microparticles. For example, it may be desirable to add further components to improve the particle rigidity or release profile. Surfactants may be used in the microparticle formulations to improve the flowability of the microparticles or to improve dispersion stability or to aid in the preparation of the initial feedstock. Examples of suitable surfactants include long-chain phospholipids, e.g. phosphatidylcholines, phosphatidylglycerols and polyethylene glycol. Other suitable surfactants include sorbitan esters, sorbitan monooleate and glycerol esters. In order to use the surfactants, it may be necessary to utilise a co-solvent system, e.g. aqueous organic solvents. Buffers and salts may also be included. Other suitable excipients will be apparent to the skilled person.

The microparticles are intended primarily for delivery via inhalation. The preferred delivery system is a dry powder inhaler (DPI), which relies entirely

on the patient's inspiratory efforts to introduce the microparticles in a dry powder form into the lungs. However, alternative inhalation devices may also be used. For example, the microparticles may be formulated for delivery using a metered dose inhaler (MDI), which usually requires a high vapour pressure propellant to force the microparticles into the respiratory tract. Nebulisers are also envisaged. These require aerosol formulations, which will be apparent to the skilled person.

In the context of dry powder inhalers, the microparticles may be formulated in compositions further comprising bulk carrier particles, which aid delivery. Suitable carrier particles are known, and include crystalline lactose particles, of a size typically in the range of from 30 to 300  $\mu\text{m}$ , more usually 50  $\mu\text{m}$  to 250  $\mu\text{m}$ . However, as the microparticles of the invention exhibit improved aerodynamic properties, it is envisaged that carrier particles will not be required. This has the added benefit of allowing more microparticles to be prepared in a single dosage form, which ensures more flexibility in the dosage regimen to be adopted for any particular therapeutic agent.

The following Examples illustrate the invention.

#### Example 1

Aqueous solutions of hyaluronic acid and insulin were prepared in a 1:1 ratio. The atomisation stage was carried out using an two-fluid nozzle air atomiser. The solution was sprayed at room temperature into a round metal container which contained stirred liquid nitrogen. The liquid feed-rate was 3.5 mls/minute through the nozzle. The sprayed particles froze immediately on contact with the liquid nitrogen. After the spraying process had been completed, the liquid nitrogen was transferred to a lyophiliser (FTS) which had been pre-chilled to -50°C. Freeze-drying occurred with a vacuum of 0.1 m bar and primary drying occurred at a shelf temperature of -20°C for 30 hours. Secondary drying was carried out at 20°C for 15 hours.

Respirable powders were provided.

#### Example 2

A solution comprising 0.2% w/v hydroxy propyl cellulose (Klucel HXF) and 0.1% w/v human serum albumin (HSA) was dispensed at room temperature

into a liquid nitrogen bath using an IVEK model AAA pump with the droplet volume adjusted to 5  $\mu$ l. The resulting frozen spheres were transferred to a pre-chilled drying chamber at -50°C. A vacuum of 0.1 mbar was then applied for 30 hours, then raised to 20°C for a further 15 hours.

5 Respirable powders were obtained.

Example 3

A warm solution comprising 0.2% w/v agarose and 0.1% w/v HSA was dispensed into a liquid nitrogen bath using a Schlick pressure nozzle, with a 0.2 mm bore. The resulting frozen droplets were transferred to a pre-chilled drying 10 chamber at -50°C. A vacuum of 0.1 mbar was then applied for 30 hours, then raised to 20°C for a further 15 hours.

Respirable, free-flowing powders were obtained which dissolved slowly.

CLAIMS

1. Microparticles obtainable by spray-freeze-drying a solution or dispersion comprising a water-soluble, matrix-forming polymer and a therapeutic agent.
2. Microparticles according to claim 1, wherein the polymer is a polysaccharide with a molecular weight greater than 500 kDa.
3. Microparticles according to claim 1 or claim 2, wherein the polymer is hyaluronic acid, or an inorganic salt thereof.
4. Microparticles according to any preceding claim, wherein the microparticles are from 1  $\mu\text{m}$  to 20  $\mu\text{m}$  in diameter.
5. Microparticles according to any preceding claim, wherein the therapeutic agent is a protein or peptide.
6. Microparticles according to claim 5, wherein the therapeutic agent is insulin.
7. Microparticles according to any preceding claim, further comprising a carbohydrate.
8. Microparticles according to any preceding claim, further comprising a surfactant.
9. A composition for pulmonary delivery, comprising microparticles according to any preceding claim, and a carrier particle.
10. A composition according to claim 9, wherein the carrier particle is from 30  $\mu\text{m}$  to 300  $\mu\text{m}$  in diameter.
11. A composition according to claim 9 or claim 10, wherein the carrier particle is lactose.
12. A device for delivery of a therapeutic agent via pulmonary inhalation, wherein the device incorporates a microparticle according to any of claims 1 to 8 or a composition according to any of claims 9 to 11.
13. Use of microparticles according to any of claims 1 to 8, in the manufacture of a composition for pulmonary administration for the treatment of disease.
14. A process for the production of microparticles suitable for pulmonary administration, comprising spray-freeze-drying a solution or dispersion comprising therapeutic agent and a hydrophilic, matrix-forming, polymer.

15. A process according to claim 14, wherein the spray-freeze-drying is carried out under conditions to produce microparticles of from 1  $\mu\text{m}$  to 20  $\mu\text{m}$  in diameter.
16. A process according to claim 14 or claim 15, wherein the polymer is  
5 hyaluronic acid, or an inorganic salt thereof.

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/GB 01/00834

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 A61K9/16 A61K9/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>WO 90 13285 A (ENZYTECH INC) 15 November 1990 (1990-11-15) page 2, line 20 -page 3, line 19 page 4, line 11 -page 6, line 7 page 6, line 25 - line 26; claims 1,2,5,7,8,11,12,14,15; examples 2,5,9</p> <p>---</p> <p>WO 97 35562 A (WATTS PETER JAMES ;DANBIOSYST UK (GB); ILLUM LISBETH (GB)) 2 October 1997 (1997-10-02) page 4, line 5 - line 24 page 15, line 1 - line 5; claims 1-5,11-18,20-27; examples 1-3,6,7 page 6, line 27 -page 8, line 11 page 9, line 8 - last line page 11, line 25 -page 12, line 11 page 13, line 1 - line 28 page 14, line 6 - line 13</p> <p>---</p> <p>---</p>	1,4-6, 13-15
X		1-5,12, 13

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

7 August 2001

Date of mailing of the international search report

20/08/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+31-70) 340-3016

Authorized officer

Marttin, E

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 01/00834

**C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 43664 A (LG CHEMICAL LIMITED ;KIM MYUNG JIN (KR); KIM SUN JIN (KR); KWON OH) 8 October 1998 (1998-10-08) cited in the application page 5, line 16 -page 6, line 26 page 7, line 4 - line 10; claims 1-5,11; examples 1-3 ---	1-5,8,13
X	EP 0 611 567 A (TEIJIN LTD) 24 August 1994 (1994-08-24)  page 4, line 6 - line 8 page 4, line 16 - line 37 page 7, line 10 -page 8, line 11 page 8, line 26 - line 28 page 8, line 35 - last line; claims; examples 1-4,7 ---	1,4,5, 7-9, 11-13
X	EP 0 517 565 A (FIDIA SPA) 9 December 1992 (1992-12-09) page 2, line 44 - last line page 3, line 55 -page 4, line 14; claims 1-3,11; examples 1-5,39,40 ---	1-6
X	US 5 922 253 A (HEALY MICHAEL S ET AL) 13 July 1999 (1999-07-13) column 1, line 29 - line 41 column 2, line 24 - line 43 column 6, line 28 - line 65 column 11, line 13 - line 29 column 10, line 48 - line 60 column 11, line 13 - line 29 column 14, line 4 - line 13; claims 1-8,11-20 ---	14,15
P,X	WO 00 59476 A (PHARMACEUTICAL DISCOVERY CORP) 12 October 2000 (2000-10-12) page 1, line 8 - line 12 page 2, line 9 - line 22 page 4, line 31 -page 5, line 11 page 8, line 10 - line 16 ---	1,2,4, 12-15
E	WO 01 19345 A (ASTRAZENECA AB ;SJOEBLOM BRITA (SE)) 22 March 2001 (2001-03-22) page 5, line 16 -page 6, line 25 page 7, line 16 -page 8, line 25 page 9, line 1 - line 6 page 12, line 1 - line 6; claims 1,5,7,8,12-18; example 1; tables 1,2 -----	1-4,8, 13-16

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/00834

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9013285	A 15-11-1990	AT 99546 T		15-01-1994
		AU 620253 B		13-02-1992
		AU 5635990 A		29-11-1990
		CA 2030551 A,C		02-11-1990
		DE 69005800 D		17-02-1994
		DE 69005800 T		19-05-1994
		DK 432232 T		31-01-1994
		EP 0432232 A		19-06-1991
		ES 2062530 T		16-12-1994
		JP 7039339 B		01-05-1995
		JP 4500527 T		30-01-1992
WO 9735562	A 02-10-1997	AU 718593 B		20-04-2000
		AU 2038497 A		17-10-1997
		CA 2250053 A		02-10-1997
		EP 0895473 A		10-02-1999
		GB 2325162 A,B		18-11-1998
		JP 2000510100 T		08-08-2000
		NO 984376 A		21-09-1998
		US 2001007665 A		12-07-2001
WO 9843664	A 08-10-1998	KR 236771 B		01-02-2000
		AU 721929 B		20-07-2000
		AU 6524198 A		22-10-1998
		BG 102969 A		30-09-1999
		BR 9804802 A		17-08-1999
		EP 0918535 A		02-06-1999
		HU 0000737 A		28-09-2000
		JP 11513047 T		09-11-1999
		NZ 333019 A		30-08-1999
		PL 330230 A		10-05-1999
		TR 9802500 T		21-06-1999
		ZA 9802533 A		30-09-1998
EP 0611567	A 24-08-1994	AU 659328 B		11-05-1995
		AU 4355693 A		04-01-1994
		JP 2907551 B		21-06-1999
		AU 660824 B		06-07-1995
		AU 4355593 A		04-01-1994
		CA 2115065 A		23-12-1993
		CA 2115444 A		23-12-1993
		EP 0606486 A		20-07-1994
		WO 9325193 A		23-12-1993
		WO 9325198 A		23-12-1993
		JP 2962578 B		12-10-1999
		KR 208979 B		15-07-1999
		US 5626871 A		06-05-1997
		US 5972388 A		26-10-1999
EP 0517565	A 09-12-1992	IT 1247472 B		17-12-1994
		AT 196991 T		15-11-2000
		CA 2070095 A		01-12-1992
		DE 69231507 D		23-11-2000
		DE 69231507 T		03-05-2001
		EP 0979648 A		16-02-2000
		ES 2153355 T		01-03-2001
		JP 7179363 A		18-07-1995
		US 6066340 A		23-05-2000

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 01/00834

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0517565	A	US	6039970 A	21-03-2000
US 5922253	A	13-07-1999	AU 719944 B AU 2362899 A AU 701992 B AU 5859296 A BR 9608370 A CA 2221496 A CN 1184420 A CZ 9703582 A EP 0827396 A HU 9802489 A JP 11505250 T NO 975269 A NZ 308763 A PL 323382 A SK 153797 A WO 9636317 A US 6153129 A	18-05-2000 27-05-1999 11-02-1999 29-11-1996 17-08-1999 21-11-1996 10-06-1998 17-06-1998 11-03-1998 28-07-1999 18-05-1999 15-01-1998 25-11-1998 30-03-1998 09-09-1998 21-11-1996 28-11-2000
WO 0059476	A	12-10-2000	NONE	
WO 0119345	A	22-03-2001	AU 7463700 A	17-04-2001